{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:53Z","timestamp":1791571793053,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/leu.2017.273","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T09:25:33Z","timestamp":1503480333000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma"],"prefix":"10.1038","volume":"32","author":[{"given":"M","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sakata-Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kiryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Tanzima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Enami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-8000","authenticated-orcid":false,"given":"M","family":"Muratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-5800","authenticated-orcid":false,"given":"K","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"T","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"BFleu2017273_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375\u20132390.","journal-title":"Blood"},{"key":"BFleu2017273_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L de Leval","year":"2010","unstructured":"de Leval L, Gisselbrecht C, Gaulard P . Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010; 148: 673\u2013689.","journal-title":"Br J Haematol"},{"key":"BFleu2017273_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 171\u2013175.","journal-title":"Nat Genet"},{"key":"BFleu2017273_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T . Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166\u2013170.","journal-title":"Nat Genet"},{"key":"BFleu2017273_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46: 371\u2013375.","journal-title":"Nat Genet"},{"key":"BFleu2017273_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11\u201324.","journal-title":"Cancer Cell"},{"key":"BFleu2017273_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronne","year":"2012","unstructured":"Couronne L, Bastard C, Bernard OA . TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012; 366: 95\u201396.","journal-title":"N Engl J Med"},{"key":"BFleu2017273_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120: 1466\u20131469.","journal-title":"Blood"},{"key":"BFleu2017273_CR9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119: 1901\u20131903.","journal-title":"Blood"},{"key":"BFleu2017273_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12185-015-1738-8","volume":"102","author":"M Sakata-Yanagimoto","year":"2015","unstructured":"Sakata-Yanagimoto M . Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol 2015; 102: 523\u2013527.","journal-title":"Int J Hematol"},{"key":"BFleu2017273_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2011.12.003","volume":"142","author":"P Rougerie","year":"2012","unstructured":"Rougerie P, Delon J . Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett 2012; 142: 1\u201313.","journal-title":"Immunol Lett"},{"key":"BFleu2017273_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1034\/j.1600-065X.2003.00028.x","volume":"192","author":"DA Cantrell","year":"2003","unstructured":"Cantrell DA . GTPases and T cell activation. Immunol Rev 2003; 192: 122\u2013130.","journal-title":"Immunol Rev"},{"key":"BFleu2017273_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.194.7.903","volume":"194","author":"I Corre","year":"2001","unstructured":"Corre I, Gomez M, Vielkind S, Cantrell DA . Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. J Exp Med 2001; 194: 903\u2013914.","journal-title":"J Exp Med"},{"key":"BFleu2017273_CR14","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.4049\/jimmunol.1400839","volume":"193","author":"S Zhang","year":"2014","unstructured":"Zhang S, Konstantinidis DG, Yang JQ, Mizukawa B, Kalim K, Lang RA et al. Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development. J Immunol 2014; 193: 5973\u20135982.","journal-title":"J Immunol"},{"key":"BFleu2017273_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.188.5.931","volume":"188","author":"SW Henning","year":"1998","unstructured":"Henning SW, Cantrell DA . p56lck signals for regulating thymocyte development can be distinguished by their dependency on Rho function. J Exp Med 1998; 188: 931\u2013939.","journal-title":"J Exp Med"},{"key":"BFleu2017273_CR16","doi-asserted-by":"publisher","first-page":"ra83","DOI":"10.1126\/scisignal.2000420","volume":"2","author":"A Saveliev","year":"2009","unstructured":"Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, Rittinger K et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation. Sci Signal 2009; 2: ra83.","journal-title":"Sci Signal"},{"key":"BFleu2017273_CR17","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1074\/jbc.275.3.2185","volume":"275","author":"MR Kuhne","year":"2000","unstructured":"Kuhne MR, Ku G, Weiss A . A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation. J Biol Chem 2000; 275: 2185\u20132190.","journal-title":"J Biol Chem"},{"key":"BFleu2017273_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.coi.2005.04.003","volume":"17","author":"VL Tybulewicz","year":"2005","unstructured":"Tybulewicz VL . Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005; 17: 267\u2013274.","journal-title":"Curr Opin Immunol"},{"key":"BFleu2017273_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1084\/jem.20011663","volume":"195","author":"LF Reynolds","year":"2002","unstructured":"Reynolds LF, Smyth LA, Norton T, Freshney N, Downward J, Kioussis D et al. Vav1 transduces T cell receptor signals to the activation of phospholipase C-gamma1 via phosphoinositide 3-kinase-dependent and -independent pathways. J Exp Med 2002; 195: 1103\u20131114.","journal-title":"J Exp Med"},{"key":"BFleu2017273_CR20","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1128\/MCB.15.8.4337","volume":"15","author":"J Wu","year":"1995","unstructured":"Wu J, Katzav S, Weiss A . A functional T-cell receptor signaling pathway is required for p95vav activity. Mol Cell Biol 1995; 15: 4337\u20134346.","journal-title":"Mol Cell Biol"},{"key":"BFleu2017273_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.biocel.2008.11.006","volume":"41","author":"S Katzav","year":"2009","unstructured":"Katzav S . Vav1: a hematopoietic signal transduction molecule involved in human malignancies. Int J Biochem Cell Biol 2009; 41: 1245\u20131248.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFleu2017273_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0092-8674(00)00085-4","volume":"102","author":"B Aghazadeh","year":"2000","unstructured":"Aghazadeh B, Lowry WE, Huang XY, Rosen MK . Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000; 102: 625\u2013633.","journal-title":"Cell"},{"key":"BFleu2017273_CR23","doi-asserted-by":"publisher","first-page":"15257","DOI":"10.1021\/bi051126h","volume":"44","author":"GK Amarasinghe","year":"2005","unstructured":"Amarasinghe GK, Rosen MK . Acidic region tyrosines provide access points for allosteric activation of the autoinhibited Vav1 Dbl homology domain. Biochemistry 2005; 44: 15257\u201315268.","journal-title":"Biochemistry"},{"key":"BFleu2017273_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cell.2009.12.033","volume":"140","author":"B Yu","year":"2010","unstructured":"Yu B, Martins IR, Li P, Amarasinghe GK, Umetani J, Fernandez-Zapico ME et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 2010; 140: 246\u2013256.","journal-title":"Cell"},{"key":"BFleu2017273_CR25","doi-asserted-by":"publisher","first-page":"ra35","DOI":"10.1126\/scisignal.2004993","volume":"7","author":"M Barreira","year":"2014","unstructured":"Barreira M, Fabbiano S, Couceiro JR, Torreira E, Martinez-Torrecuadrada JL, Montoya G et al. The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins. Sci Signal 2014; 7: ra35.","journal-title":"Sci Signal"},{"key":"BFleu2017273_CR26","doi-asserted-by":"publisher","first-page":"42964","DOI":"10.1074\/jbc.M207401200","volume":"277","author":"WT Arthur","year":"2002","unstructured":"Arthur WT, Ellerbroek SM, Der CJ, Burridge K, Wennerberg K . XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J Biol Chem 2002; 277: 42964\u201342972.","journal-title":"J Biol Chem"},{"key":"BFleu2017273_CR27","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","volume":"128","author":"RL Boddicker","year":"2016","unstructured":"Boddicker RL, Razidlo GL, Dasari S, Zeng Y, Hu G, Knudson RA et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 2016; 128: 1234\u20131245.","journal-title":"Blood"},{"key":"BFleu2017273_CR28","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 2016; 128: 1490\u20131502.","journal-title":"Blood"},{"key":"BFleu2017273_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1073\/pnas.1608839114","volume":"114","author":"F Abate","year":"2017","unstructured":"Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc Natl Acad Sci USA 2017; 114: 764\u2013769.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017273_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri2818","volume":"10","author":"MR Muller","year":"2010","unstructured":"Muller MR, Rao A . NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010; 10: 645\u2013656.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2017273_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA . CD28 costimulation: from mechanism to therapy. Immunity 2016; 44: 973\u2013988.","journal-title":"Immunity"},{"key":"BFleu2017273_CR32","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","volume":"100","author":"SH Lee","year":"2015","unstructured":"Lee SH, Kim JS, Kim J, Kim SJ, Kim WS, Lee S et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica 2015; 100: e505\u2013e507.","journal-title":"Haematologica"},{"key":"BFleu2017273_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2404045","volume":"20","author":"B Streubel","year":"2006","unstructured":"Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A . Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 2006; 20: 313\u2013318.","journal-title":"Leukemia"},{"key":"BFleu2017273_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","volume":"101","author":"HY Yoo","year":"2016","unstructured":"Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 2016; 101: 757\u2013763.","journal-title":"Haematologica"},{"key":"BFleu2017273_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM . B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015; 52: 77\u201385.","journal-title":"Semin Hematol"},{"key":"BFleu2017273_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/ajh.24203","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA . A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol 2016; 91: 113\u2013122.","journal-title":"Am J Hematol"},{"key":"BFleu2017273_CR37","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.1501841","volume":"196","author":"GJ Martinez","year":"2016","unstructured":"Martinez GJ, Hu JK, Pereira RM, Crampton JS, Togher S, Bild N et al. Cutting edge: NFAT transcription factors promote the generation of follicular helper T cells in response to acute viral infection. J Immunol 2016; 196: 2015\u20132019.","journal-title":"J Immunol"},{"key":"BFleu2017273_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nature06253","volume":"450","author":"D Yu","year":"2007","unstructured":"Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007; 450: 299\u2013303.","journal-title":"Nature"},{"key":"BFleu2017273_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2011-07-365130","volume":"120","author":"JI Ellyard","year":"2012","unstructured":"Ellyard JI, Chia T, Rodriguez-Pinilla SM, Martin JL, Hu X, Navarro-Gonzalez M et al. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood 2012; 120: 812\u2013821.","journal-title":"Blood"},{"issue":"2 Suppl","key":"BFleu2017273_CR40","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.1016\/j.transproceed.2004.01.018","volume":"36","author":"MH Kapturczak","year":"2004","unstructured":"Kapturczak MH, Meier-Kriesche HU, Kaplan B . Pharmacology of calcineurin antagonists. Transplant Proc 2004; 36 (2 Suppl): 25S\u201332S.","journal-title":"Transplant Proc"},{"key":"BFleu2017273_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10428190601137658","volume":"48","author":"R Advani","year":"2007","unstructured":"Advani R, Horwitz S, Zelenetz A, Horning SJ . Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007; 48: 521\u2013525.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017273_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.5732\/cjc.011.10071","volume":"30","author":"XG Chen","year":"2011","unstructured":"Chen XG, Huang H, Tian Y, Guo CC, Liang CY, Gong YL et al. Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen. Chin J Cancer 2011; 30: 731\u2013738.","journal-title":"Chin J Cancer"},{"key":"BFleu2017273_CR43","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu2017273_CR44","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Ocana A, Pandiella A . Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546\u20135552.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017273_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/gcc.22202","volume":"53","author":"M Rohde","year":"2014","unstructured":"Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer 2014; 53: 911\u2013916.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2017273_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood-2015-06-644948","volume":"127","author":"Y Nagata","year":"2015","unstructured":"Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y et al. Variegated RHOA mutations in adult T-cell leukemia\/lymphoma. Blood 2015; 127: 596\u2013604.","journal-title":"Blood"},{"key":"BFleu2017273_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 2014; 46: 583\u2013587.","journal-title":"Nat Genet"},{"key":"BFleu2017273_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood-2015-12-683458","volume":"127","author":"S Ishikawa","year":"2016","unstructured":"Ishikawa S . Opposite RHOA functions within the ATLL category. Blood 2016; 127: 524\u2013525.","journal-title":"Blood"},{"key":"BFleu2017273_CR49","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet 2015; 47: 1304\u20131315.","journal-title":"Nat Genet"},{"key":"BFleu2017273_CR50","doi-asserted-by":"crossref","first-page":"28731","DOI":"10.18632\/oncotarget.5086","volume":"6","author":"S Katzav","year":"2015","unstructured":"Katzav S . Vav1: A Dr. Jekyll and Mr. Hyde protein\u2014good for the hematopoietic system, bad for cancer. Oncotarget 2015; 6: 28731\u201328742.","journal-title":"Oncotarget"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017273","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:09:38Z","timestamp":1684433378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["BFleu2017273"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.273","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]},"assertion":[{"value":"20 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SC received research funding from Bristol-Meyer Squibb that markets dasatinib.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}